Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the multinational trials to obtain the most precise estimates of the magnitude of treatment effect on measures of dise...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur Respir J
Prif Awduron: Noble, Paul W., Albera, Carlo, Bradford, Williamson Z., Costabel, Ulrich, du Bois, Roland M., Fagan, Elizabeth A., Fishman, Robert S., Glaspole, Ian, Glassberg, Marilyn K., Lancaster, Lisa, Lederer, David J., Leff, Jonathan A., Nathan, Steven D., Pereira, Carlos A., Swigris, Jeffrey J., Valeyre, Dominique, King, Talmadge E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: European Respiratory Society 2016
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4697914/
https://ncbi.nlm.nih.gov/pubmed/26647432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00026-2015
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg